Options paper proposes limits on process for the most important technologies

February 13, 2024 Latest News BioPharma Comment

This is a preview of subscriber content

Subscribe now to continue reading.

Of all the proposals in the Health Technology Assessment Review options paper, one of the most significant is a proposed resubmission cap for technologies identified as the most important. …

Subscribe now to continue reading.

Latest Video

'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame'
April 22, 2025 - Latest News
Australia increasingly isolated after Europe approves Alzheimer's therapy
April 22, 2025 - BioPharma
Lilly records another win in weight loss in trial of oral GLP-1 agonist
April 22, 2025 - Latest News
'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'
April 23, 2025 - Latest News
Pharmac proposes three-monthly quantities for popular asthma inhalers
April 22, 2025 - Latest News

Options paper proposes limits on process for the most important technologies

This is a preview of subscriber content

Latest Video

Most Read

'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame'

Australia increasingly isolated after Europe approves Alzheimer's therapy

Lilly records another win in weight loss in trial of oral GLP-1 agonist

'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'

Pharmac proposes three-monthly quantities for popular asthma inhalers

New Stories

Roche announces historic investment to build US manufacturing base

'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'

US trade agenda looks mostly disinterested in pharmaceuticals

Mesoblast says Ryoncil payer coverage extended to over 100 million Americans

Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial

Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel

Race says patient enrolment opened at second site for RC220 solid tumour trial

Sign In

Options paper proposes limits on process for the most important technologies

This is a preview of subscriber content

Latest Video

Most Read

'Arguing over the proverbial lifejacket whilst patients are in the water drowning. Shame'

Australia increasingly isolated after Europe approves Alzheimer's therapy

Lilly records another win in weight loss in trial of oral GLP-1 agonist

'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'

Pharmac proposes three-monthly quantities for popular asthma inhalers

Follow Us

New Stories

Roche announces historic investment to build US manufacturing base

'Reflecting the experience of people living with cancer, Pfizer’s new campaign Part of the Story seeks to reshape the narrative'

US trade agenda looks mostly disinterested in pharmaceuticals

Mesoblast says Ryoncil payer coverage extended to over 100 million Americans

Anatara provides update following completion of analysis of Phase 2 GaRP-IBS clinical trial

Recce Phase 2 trial receives additional approval for treating diabetic patients with topical gel

Race says patient enrolment opened at second site for RC220 solid tumour trial